Berkshire Hathaway reported a strong second quarter with manufacturing revenues up 15.2% and pre-tax earnings growing 25.8%, driven by organic and acquisition growth in units like Precision Castparts and OxyChem. Under CEO Greg Abel, the company has been active in capital allocation, including significant purchases of Alphabet shares, acquiring Taylor Morrison, and $4.5 billion in share buybacks, all done with a disciplined value approach. The analyst rates the stock a cautious Buy, recommending gradual accumulation as the stock trades near its five-year price-to-book average and management remains prudent.
Warren Buffett's 2016 acquisition of Precision Castparts, initially seen as overpriced and written down by $11 billion, is now gaining value due to a surge in demand for its complex metal components used in aerospace and energy sectors. GE Aerospace'...
Berkshire Hathaway, under new leadership by Greg Abel, is adjusting its portfolio with $19.8 billion in net equity purchases and $4.5 billion in share buybacks during Q2. The company is increasing exposure to Alphabet and homebuilders while maintaini...
Berkshire Hathaway is entering a new phase of growth driven by resumed share buybacks and organic profit growth. The company also increased its equity portfolio exposure to technology stocks, which may enhance long-term compounding returns. This stra...
VistaShares Target 15 Berkshire Select Income ETF (OMAH) has outperformed Berkshire Hathaway since its IPO in March 2025 by delivering a consistent 15% annual yield. The fund holds 10% Berkshire Hathaway stock and 90% equally weighted top US Berkshir...
